AEON Biopharma (NASDAQ:AEON – Get Free Report) and Evofem Biosciences (NASDAQ:EVFM – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.
Earnings and Valuation
This table compares AEON Biopharma and Evofem Biosciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AEON Biopharma | N/A | N/A | -$36.63 million | ($5.00) | -0.16 |
| Evofem Biosciences | $11.39 million | 0.09 | $52.98 million | ($0.07) | -0.11 |
Insider and Institutional Ownership
22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares AEON Biopharma and Evofem Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AEON Biopharma | N/A | N/A | -994.63% |
| Evofem Biosciences | -46.42% | -91.97% | -61.93% |
Analyst Recommendations
This is a summary of recent recommendations for AEON Biopharma and Evofem Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AEON Biopharma | 0 | 1 | 1 | 1 | 3.00 |
| Evofem Biosciences | 0 | 0 | 0 | 0 | 0.00 |
Volatility and Risk
AEON Biopharma has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -1.32, indicating that its share price is 232% less volatile than the S&P 500.
Summary
AEON Biopharma beats Evofem Biosciences on 9 of the 13 factors compared between the two stocks.
About AEON Biopharma
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
About Evofem Biosciences
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Receive News & Ratings for AEON Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEON Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
